Norge -
norsk -
Statens legemiddelverk
provera 10 mg
pfizer as - medroksyprogesteronacetat - tablett - 10 mg
Norge -
norsk -
Statens legemiddelverk
salazopyrin en 500 mg
pfizer as - sulfasalazin - enterotablett - 500 mg
Norge -
norsk -
Statens legemiddelverk
synarela 200 mikrog/ dose
pfizer as - nafarelinacetat - nesespray, oppløsning - 200 mikrog/ dose
Norge -
norsk -
Statens legemiddelverk
synfase -
pfizer as - noretisteron / etinyløstradiol - tablett
Norge -
norsk -
Statens legemiddelverk
ticovac 2.4 mikrog/ sprøyte
pfizer as - skogflåttencefalittvirus (tbe), inaktivert - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 2.4 mikrog/ sprøyte
Norge -
norsk -
Statens legemiddelverk
ticovac junior 1.2 mikrog/ sprøyte
pfizer as - skogflåttencefalittvirus (tbe), inaktivert - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 1.2 mikrog/ sprøyte
Norge -
norsk -
Statens legemiddelverk
terra-cortril 30 mg/ g / 10 mg/ g
pfizer as - oksytetrasyklinhydroklorid / hydrokortison - salve - 30 mg/ g / 10 mg/ g
Norge -
norsk -
Statens legemiddelverk
terramycin-polymyxin b 30 mg/ g / 10000 ie/ g
pfizer as - oksytetrasyklinhydroklorid / polymyksin b sulfat - salve - 30 mg/ g / 10000 ie/ g
Norge -
norsk -
Statens legemiddelverk
zeldox 80 mg
pfizer as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 80 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
lorviqua
pfizer europe ma eeig - lorlatinib - karsinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.